STOCK TITAN

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
management

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on cancer immunotherapies, has appointed PricewaterhouseCoopers LLP (PwC US) as its independent registered public accounting firm for fiscal year 2024. This decision, approved by the Audit Committee, is part of I-Mab's strategic transition to become a fully U.S.-based biotech company. The change aims to ensure compliance with the Holding Foreign Companies Accountable Act and aligns with the company's long-term growth objectives.

Interim CEO Sean Fu emphasized that this appointment marks a significant milestone in I-Mab's U.S. transition strategy. CFO Joseph Skelton expressed enthusiasm about working with PwC US, viewing it as beneficial for shareholders. The company assures that this transition was not due to any disagreements or issues with the previous auditor.

I-Mab (NASDAQ: IMAB), un'azienda biotecnologica globale con sede negli Stati Uniti, focalizzata sulle immunoterapie contro il cancro, ha nominato PricewaterhouseCoopers LLP (PwC US) come suo ente di revisione contabile pubblico indipendente per l'esercizio fiscale 2024. Questa decisione, approvata dal Comitato di Revisione, fa parte della transizione strategica di I-Mab per diventare un'azienda biotecnologica interamente basata negli Stati Uniti. Il cambiamento mira a garantire la conformità con il Holding Foreign Companies Accountable Act e si allinea con gli obiettivi di crescita a lungo termine dell'azienda.

Il CEO ad interim Sean Fu ha sottolineato che questa nomina segna un traguardo significativo nella strategia di transizione di I-Mab negli Stati Uniti. Il CFO Joseph Skelton ha espresso entusiasmo per la collaborazione con PwC US, considerandola vantaggiosa per gli azionisti. L'azienda assicura che questa transizione non è stata causata da disaccordi o problemi con il revisore precedente.

I-Mab (NASDAQ: IMAB), una empresa biotecnológica global con sede en EE. UU. centrada en las inmunoterapias contra el cáncer, ha nombrado a PricewaterhouseCoopers LLP (PwC US) como su firma de contabilidad pública registrada e independiente para el año fiscal 2024. Esta decisión, aprobada por el Comité de Auditoría, es parte de la transición estratégica de I-Mab para convertirse en una empresa biotecnológica completamente basada en EE. UU. El cambio tiene como objetivo asegurar el cumplimiento de la Holding Foreign Companies Accountable Act y se alinea con los objetivos de crecimiento a largo plazo de la compañía.

El CEO interino Sean Fu enfatizó que este nombramiento marca un hito significativo en la estrategia de transición de I-Mab en EE. UU. El CFO Joseph Skelton expresó entusiasmo por trabajar con PwC US, considerándolo beneficioso para los accionistas. La empresa asegura que esta transición no se debe a desacuerdos o problemas con el auditor anterior.

I-Mab (NASDAQ: IMAB), 미국에 본사를 둔 글로벌 생명공학 회사로 암 면역 치료에 중점을 두고 있는 I-Mab이 PricewaterhouseCoopers LLP (PwC US)를 2024 회계연도 독립 등록 공인 회계 감사인으로 임명했습니다. 이 결정은 감사 위원회에 의해 승인되었으며, I-Mab이 전적으로 미국에 기반을 둔 생명공학 회사로의 전략적 전환의 일환입니다. 이 변화는 Holding Foreign Companies Accountable Act 준수를 보장하고 회사의 장기 성장 목표에 일치하는 것을 목표로 하고 있습니다.

임시 CEO인 Sean Fu는 이번 임명이 I-Mab의 미국 전환 전략에서 중요한 이정표가 되는 것이라고 강조했습니다. CFO인 Joseph Skelton은 PwC US와의 협업에 대한 기대를 표명하며, 이를 주주들에게 유리하다고 여겼습니다. 회사는 이번 전환이 이전 감사인과의 불일치나 문제로 인한 것이 아님을 확언합니다.

I-Mab (NASDAQ: IMAB), une entreprise biopharmaceutique mondiale basée aux États-Unis et axée sur les immunothérapies contre le cancer, a nommé PricewaterhouseCoopers LLP (PwC US) comme son cabinet d'expertise comptable public indépendant pour l'exercice fiscal 2024. Cette décision, approuvée par le Comité d'Audit, fait partie de la transition stratégique d'I-Mab pour devenir une entreprise biopharmaceutique entièrement basée aux États-Unis. Ce changement vise à garantir la conformité avec la Holding Foreign Companies Accountable Act et s'aligne avec les objectifs de croissance à long terme de l'entreprise.

Le PDG par intérim Sean Fu a souligné que cette nomination représente une étape importante dans la stratégie de transition d'I-Mab aux États-Unis. Le directeur financier Joseph Skelton a exprimé son enthousiasme pour travailler avec PwC US, le considérant bénéfique pour les actionnaires. L'entreprise assure que cette transition n'est pas due à des désaccords ou des problèmes avec l'auditeur précédent.

I-Mab (NASDAQ: IMAB), ein globales Biotechnologieunternehmen mit Sitz in den USA, das sich auf Immuntherapien gegen Krebs konzentriert, hat PricewaterhouseCoopers LLP (PwC US) als seine unabhängige registrierte Wirtschaftsprüfungsgesellschaft für das Geschäftsjahr 2024 ernannt. Diese Entscheidung, die vom Prüfungsausschuss genehmigt wurde, ist Teil von I-Mabs strategischer Transition, um ein vollständig in den USA ansässiges Biotechnologieunternehmen zu werden. Der Wechsel zielt darauf ab, die Einhaltung des Holding Foreign Companies Accountable Act zu gewährleisten und entspricht den langfristigen Wachstumszielen des Unternehmens.

Interim-CEO Sean Fu betonte, dass diese Ernennung einen bedeutenden Meilenstein in I-Mabs US-Transition-Strategie darstellt. CFO Joseph Skelton äußerte Enthusiasmus über die Zusammenarbeit mit PwC US und sieht diese als vorteilhaft für die Aktionäre. Das Unternehmen versichert, dass dieser Übergang nicht aufgrund von Meinungsverschiedenheiten oder Problemen mit dem vorherigen Prüfer erfolgt ist.

Positive
  • Appointment of a reputable U.S. auditor (PwC) may enhance credibility with investors
  • Strategic move towards becoming a full-fledged U.S.-based biotech company
  • Ensures compliance with the Holding Foreign Companies Accountable Act
Negative
  • Potential increase in audit costs due to engagement of a major U.S. accounting firm

Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech

PwC to serve as independent registered public accounting firm for FY 2024

ROCKVILLE, Md., Aug. 7, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) ("I-Mab", the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that the Audit Committee of its Board of Directors has approved the appointment of PricewaterhouseCoopers LLP (U.S.) ("PwC US") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, effective immediately.

"I-Mab continues to achieve excellent progress towards our strategic objective of becoming a U.S.-based biotech," said Sean Fu, PhD, Board Member and Interim Chief Executive Officer of I-Mab. "The appointment of PwC US as our U.S. auditor is another important milestone in this transition, underscoring our progress and commitment to the strategy and vision defined by the Board."

I-Mab expects that the transition to a U.S. audit firm will enable the Company to continue to comply with the audit requirements of the Holding Foreign Companies Accountable Act and facilitate the continued transition of the Company to a full-fledged U.S.-based biotech company. This transition was not the result of any disagreements, reportable events, modified opinions, or unresolved matters with the Company's previous auditor, and no matters regarding the transition need to be brought to the attention of the Company's shareholders.

"We are enthusiastic to work with PwC US and believe that their engagement as our U.S. auditor aligns with the long-term interests of our shareholders," said Joseph Skelton, Chief Financial Officer of I-Mab. "We continue to grow and advance our organization and corporate governance with a focus on supporting I-Mab's long-term growth and look forward to keeping investors up to date on our progress."

For more information on this change in the Company's independent registered public accounting firm, please refer to the 6-K filing that the Company filed with the U.S. Securities and Exchange Commission ("SEC") today, available on the Company's website at www.i-mabbiopharma.com and on the SEC's website at www.sec.gov.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer.

I-Mab has established operations in Rockville, Maryland. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

Forward Looking Statements

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "believes", "designed to", "anticipates", "future", "intends", "plan", "promise", "potential", "estimate", "confident", "explore", "optimistic about", "look forward to", and similar terms or the negative thereof. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. The forward-looking statements in this press release include, without limitation, statements regarding the engagement of PwC US and expectations relating to the impact of such engagement on compliance with audit requirements and the Company's transition to a U.S.-based biotech company. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or New Drug Application/Biologics License Application approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and discussions of potential risks, uncertainties, and other important factors in  I-Mab's most recent annual report on Form 20-F and I-Mab's subsequent filings with the SEC. I-Mab may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

I-Mab Contacts

Investors & Media

Tyler Ehler

Senior Director, Investor Relations

IR@imabbio.com 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-appoints-us-auditor-pricewaterhousecoopers-llp-pwc-302216494.html

SOURCE I-Mab Biopharma

FAQ

Why did I-Mab (IMAB) appoint PricewaterhouseCoopers LLP as its new auditor?

I-Mab appointed PwC US as part of its strategic transition to become a fully U.S.-based biotech company and to ensure compliance with the Holding Foreign Companies Accountable Act.

When will PricewaterhouseCoopers LLP start auditing I-Mab (IMAB)?

PwC US will serve as I-Mab's independent registered public accounting firm for the fiscal year ending December 31, 2024, effective immediately from the announcement date.

Were there any disagreements with I-Mab's (IMAB) previous auditor?

No, I-Mab stated that the transition to PwC US was not the result of any disagreements, reportable events, modified opinions, or unresolved matters with the company's previous auditor.

How does the appointment of PwC affect I-Mab's (IMAB) shareholders?

I-Mab believes that engaging PwC US as their U.S. auditor aligns with the long-term interests of their shareholders and supports the company's long-term growth strategy.

I-MAB American Depositary Shares

NASDAQ:IMAB

IMAB Rankings

IMAB Latest News

IMAB Stock Data

85.58M
62.31M
11.16%
30.88%
0.76%
Biotechnology
Healthcare
Link
United States of America
Rockville